Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy

Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines

Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms

(NEW YORK and SOMERSET, N.J., June 19, 2019) – Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions.

Through the years, the Anagni plant has served as one of the primary launch facilities for new medicines from Bristol-Myers Squibb that have helped millions of people in the fight against serious diseases such as cancer and cardiovascular disease. Upon closing, Catalent will continue to manufacture Bristol-Myers Squibb’s current product portfolio at the site.

By enhancing its own global network with the Anagni plant, Catalent will bring potential new customers to the site for both biologics and oral solid dose manufacturing and packaging. In particular, this facility will provide Catalent biologics customers with access to an advanced sterile drug product fill/finish and packaging capacity in Europe to complement its existing sterile fill/finish capabilities in Belgium and its drug substance, analytical and fill/finish capabilities in North America.

“We believe that the sale to Catalent will continue the vital role the Anagni facility plays for its workforce, the community and patients,” said Lou Schmukler, President, Global Product Development and Supply, Bristol-Myers Squibb. “This marks an important step in the ongoing evolution of our manufacturing network to support the company’s innovative product portfolio. Bristol-Myers Squibb has a long history in Italy, and we intend to maintain a continued strategic presence in Italy, which is critical for our ability to deliver transformational medicines to patients.”

Alessandro Maselli, Catalent’s President and Chief Operating Officer, commented, “The addition of the Anagni facility provides our European customers with great biologics and oral dose capabilities to accelerate their development programs and improve commercial supply.” He added, “Bristol-Myers Squibb has invested in the facility to create a center of excellence for new product launches with a robust quality and delivery record, and an employee base who shares Catalent’s operational excellence and patient focus.”

William Blair & Company served as financial advisor to Bristol-Myers Squibb.

ABOUT THE ANAGNI FACILITY

The Bristol-Myers Squibb Anagni facility is a pharmaceutical manufacturing plant, situated in an industrial area one hundred kilometers southeast of Rome. The site opened in 1966. The facility floor space is approximately 19,300 square meters on a site of 34 hectares. The Anagni facility manufactures and packages cardiovascular, neuroleptics, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics.

ABOUT BRISTOL-MYERS SQUIBB

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

BRISTOL-MYERS SQUIBB FORWARD-LOOKING STATEMENT

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the proposed transaction. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, the completion of the information and consultation processes with relevant employee representative bodies in connection with the proposed transaction, the parties’ ability to satisfy certain closing conditions, any delay or inability of Bristol-Myers Squibb to realize the expected benefits of the proposed transaction and that the proposed transaction will close on the terms or within the time frame described in this document. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2018, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol-Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

CATALENT FORWARD-LOOKING STATEMENT NOTICE

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the proposed transaction. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, the completion of the information and consultation processes with relevant employee representative bodies in connection with the proposed transaction, the parties’ ability to satisfy certain closing conditions, any delay or inability of Catalent to realize the expected benefits of the proposed transaction and whether the proposed transaction will close on the terms or within the time frame described in this press release. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Catalent’s business, particularly those identified in the risk factors discussion in Catalent’s Annual Report on Form 10-K for the year ended June 30, 2018 and other filings by Catalent with the Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this press release, and, except as otherwise required by federal securities law, Catalent undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Contacts

Bristol-Myers Squibb
Media:

U.S. – Priyanka Shah, +1-609-252-7602, Priyanka.shah1@bms.com
Italy – Antonella Iacovelli, 0039-348521107, antonella.iacovelli@bms.com

Investors:
Tim Power, +1-609-252-7509, timothy.power@bms.com

Catalent, Inc.
Media:
Chris Halling, +44 (0)7580 041073, chris.halling@catalent.com
Richard Kerns, NEPR, +44 (0)161 728 5880

Investors:
Tom Castellano, +1-732-537-6175, thomas.castellano@catalent.com